Clinical trial · no report yet · Phase 3
SAFFRON
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
- NCT05261399 ↗
- Active, not recruiting
- AstraZeneca
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Carcinoma; Non-Small-Cell Lung
- Interventions
- Savolitinib; Osimertinib; Pemetrexed; Cisplatin; Carboplatin
- Arms
- Chemotherapy · Active comparator
- Savolitinib + Osimertinib · Experimental
- Enrollment
- 341
- Primary outcomes
- Progression-free survival (PFS) / savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on osimertinib.
- Sponsor
- AstraZeneca
- Start
- Aug 3, 2022
- Primary completion
- Jul 6, 2026
- Results posted
- No
- Registry record
- NCT05261399 · updated Aug 6, 2026